After a brutal year at the helm, Incyte CEO Hervé Hoppenot took a big cut in annual compensation for 2018 — but he still made more than GSK CEO Emma Walmsley.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription